Evaxion Biotech A/S ADR (EVAX)

$1.66 +0.02 (1.22%)
Market Cap 2.30M
Revenue (ttm) 3.34M
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -316.47%
Debt to Equity Ratio -4.95
Volume 57,600
Avg Vol 68,002
Day's Range N/A - N/A
Shares Out 1.40M
Stochastic %K 76%
Beta -0.24
Analysts Strong Sell
Price Target $13.25

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a m...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 53 53 18 50
Website: evaxion.ai
Address:
Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark
ChaChing777
ChaChing777 Jun. 4 at 5:14 PM
$EVAX Feels like something is brewing. We’re getting some movement in the right direction. 
1 · Reply
TheDragonsClaw
TheDragonsClaw Jun. 4 at 9:27 AM
$SEGG $CPIX $IBO $EVAX Need more news!
0 · Reply
topstockalerts
topstockalerts Jun. 3 at 10:20 PM
$EVAX the chart is starting to attract more attention.
0 · Reply
ChaChing777
ChaChing777 Jun. 3 at 9:31 PM
$EVAX Hopefully soon. This things take a little time.
1 · Reply
Whtmtn
Whtmtn Jun. 3 at 12:31 PM
$EVAX any strategic deals happening here per Helen’s repeated claims of progress?
0 · Reply
Manwiththeplan
Manwiththeplan Jun. 3 at 10:55 AM
$EVAX i am a big fan of the science here. But i am now waiting 2 years for significant new business developement. I gave it to may 2026 and now i will be reducing my position a bit. Made profit during last run up, but i am losing faith a bit
3 · Reply
Manwiththeplan
Manwiththeplan Jun. 2 at 6:20 PM
$EVAX
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 2 at 12:06 AM
$EVAX
0 · Reply
NoNoNoNoNoNoYesNo
NoNoNoNoNoNoYesNo May. 27 at 7:41 PM
$EVAX I bought more today below 4. Still holding for that next pump. Just a matter of time
0 · Reply
Manwiththeplan
Manwiththeplan May. 23 at 7:20 PM
$BCTX $EVAX are my best voor 2026. Low market caps. High potential
1 · Reply
Latest News on EVAX
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

May 12, 2026, 9:30 AM EDT - 23 days ago

Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress

Evaxion Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 weeks ago

Evaxion Earnings Call Transcript: Q1 2026

Evaxion Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 weeks ago

Evaxion Earnings release: Q1 2026

Evaxion Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 weeks ago

Evaxion Slides: Q1 2026

Evaxion announces business update and first quarter 2026 financial results

May 7, 2026, 7:30 AM EDT - 4 weeks ago

Evaxion announces business update and first quarter 2026 financial results

Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

May 4, 2026, 8:00 AM EDT - 4 weeks ago

Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026

Evaxion Biotech management to meet with Maxim

2026-04-27T16:25:27.000Z - 5 weeks ago

Evaxion Biotech management to meet with Maxim

Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer

Evaxion says EVX-01 demonstrates 86% vaccine target precision in trial

2026-04-17T19:15:15.000Z - 6 weeks ago

Evaxion says EVX-01 demonstrates 86% vaccine target precision in trial

Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Apr 17, 2026, 3:10 PM EDT - 6 weeks ago

Evaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Evaxion Biotech announces new data to be presented at AACR meeting

2026-04-17T19:05:59.000Z - 6 weeks ago

Evaxion Biotech announces new data to be presented at AACR meeting

Evaxion concludes Annual General Meeting

Apr 16, 2026, 11:30 AM EDT - 7 weeks ago

Evaxion concludes Annual General Meeting

Evaxion Biotech reports last patient visit in one-year extension of EVX-01 trial

2026-04-07T12:55:09.000Z - 2 months ago

Evaxion Biotech reports last patient visit in one-year extension of EVX-01 trial

MRK

Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress

Mar 30, 2026, 8:00 AM EDT - 2 months ago

Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress

Notice to convene Evaxion's Annual General Meeting

Mar 19, 2026, 9:00 AM EDT - 2 months ago

Notice to convene Evaxion's Annual General Meeting

Evaxion Biotech assumed with a Buy at JonesResearch

2026-03-09T20:11:13.000Z - 3 months ago

Evaxion Biotech assumed with a Buy at JonesResearch

Evaxion Biotech price target lowered to $9 from $11 at Lake Street

2026-03-09T12:45:55.000Z - 3 months ago

Evaxion Biotech price target lowered to $9 from $11 at Lake Street

Evaxion Earnings Call Transcript: Q4 2025

Mar 6, 2026, 8:30 AM EST - 3 months ago

Evaxion Earnings Call Transcript: Q4 2025

Evaxion Annual report: Q4 2025

Mar 6, 2026, 8:30 AM EST - 3 months ago

Evaxion Annual report: Q4 2025

Evaxion Earnings release: Q4 2025

Mar 6, 2026, 8:30 AM EST - 3 months ago

Evaxion Earnings release: Q4 2025

Evaxion Annual report: Q4 2025

Mar 6, 2026, 8:30 AM EST - 3 months ago

Evaxion Annual report: Q4 2025

Evaxion Slides: Q4 2025

Mar 6, 2026, 8:30 AM EST - 3 months ago

Evaxion Slides: Q4 2025

Evaxion Biotech reports Q4 EPS (2c) vs. (21c) last year

2026-03-05T14:36:58.000Z - 3 months ago

Evaxion Biotech reports Q4 EPS (2c) vs. (21c) last year

Evaxion Biotech sees FY26 capex ‘similar’ to FY25

2026-03-05T14:36:19.000Z - 3 months ago

Evaxion Biotech sees FY26 capex ‘similar’ to FY25

Evaxion announces business update and full year 2025 financial results

Mar 5, 2026, 9:28 AM EST - 3 months ago

Evaxion announces business update and full year 2025 financial results

Evaxion Biotech to ‘slightly delay’ filing of 2025 report

2026-03-05T13:42:35.000Z - 3 months ago

Evaxion Biotech to ‘slightly delay’ filing of 2025 report

Evaxion plans to file 2025 annual report later today

Mar 5, 2026, 8:02 AM EST - 3 months ago

Evaxion plans to file 2025 annual report later today

Evaxion to announce business update and full year 2025 financial results on March 5, 2026

Mar 2, 2026, 8:00 AM EST - 3 months ago

Evaxion to announce business update and full year 2025 financial results on March 5, 2026

Evaxion Biotech initiated with a Buy at Maxim

2026-02-19T13:29:15.000Z - 3 months ago

Evaxion Biotech initiated with a Buy at Maxim

Evaxion Biotech expands AI-Immunology platform into autoimmune diseases

2026-01-13T13:26:14.000Z - 5 months ago

Evaxion Biotech expands AI-Immunology platform into autoimmune diseases

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Jan 13, 2026, 8:00 AM EST - 5 months ago

Evaxion expands AI-Immunology™ platform into autoimmune diseases

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

Jan 7, 2026, 8:00 AM EST - 5 months ago

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Dec 19, 2025, 7:00 AM EST - 5 months ago

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Evaxion Transcript: Sidoti's Year End Virtual Investor Conference

Dec 11, 2025, 8:30 AM EST - 6 months ago

Evaxion Transcript: Sidoti's Year End Virtual Investor Conference

Evaxion Biotech presents new data for EVX-04

2025-12-07T18:15:11.000Z - 6 months ago

Evaxion Biotech presents new data for EVX-04

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Dec 6, 2025, 2:00 PM EST - 6 months ago

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Evaxion Biotech files to sell 38.45M ordinary shares for holders

2025-11-21T13:50:16.000Z - 6 months ago

Evaxion Biotech files to sell 38.45M ordinary shares for holders

Evaxion Registration statement: Registration Filing

Nov 21, 2025, 7:00 AM EST - 6 months ago

Evaxion Registration statement: Registration Filing

Evaxion Biotech announces data for CMV vaccine program EVX-V1

2025-11-20T13:10:30.000Z - 7 months ago

Evaxion Biotech announces data for CMV vaccine program EVX-V1

Evaxion announce 2026 financial calendar

Nov 12, 2025, 8:00 AM EST - 7 months ago

Evaxion announce 2026 financial calendar

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Nov 7, 2025, 5:10 PM EST - 7 months ago

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

Evaxion Earnings Call Transcript: Q3 2025

Evaxion Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

Evaxion Earnings release: Q3 2025

Evaxion Biotech reports Q3 EPS 1c vs (4c) last year

2025-11-06T12:46:47.000Z - 7 months ago

Evaxion Biotech reports Q3 EPS 1c vs (4c) last year

Evaxion announces business update and third quarter 2025 financial results

Nov 6, 2025, 7:30 AM EST - 7 months ago

Evaxion announces business update and third quarter 2025 financial results

Evaxion Biotech expands R&D pipeline with EVX-04

2025-11-03T14:11:16.000Z - 7 months ago

Evaxion Biotech expands R&D pipeline with EVX-04

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Nov 3, 2025, 9:00 AM EST - 7 months ago

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 9:05 AM EDT - 7 months ago

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 8:00 AM EDT - 7 months ago

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Evaxion Biotech raises $7.2M, extends cash runway to 2H27

2025-10-30T12:21:10.000Z - 7 months ago

Evaxion Biotech raises $7.2M, extends cash runway to 2H27

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Oct 30, 2025, 8:00 AM EDT - 7 months ago

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Evaxion Transcript: Study Update

Oct 22, 2025, 10:30 AM EDT - 8 months ago

Evaxion Transcript: Study Update

Evaxion Press release: Study Update

Oct 22, 2025, 10:30 AM EDT - 8 months ago

Evaxion Press release: Study Update

Evaxion Slides: Study Update

Oct 22, 2025, 10:30 AM EDT - 8 months ago

Evaxion Slides: Study Update

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Oct 17, 2025, 8:15 AM EDT - 8 months ago

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion Slides: Corporate Presentation

Oct 15, 2025, 7:00 AM EDT - 8 months ago

Evaxion Slides: Corporate Presentation

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Oct 13, 2025, 8:00 AM EDT - 8 months ago

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Oct 8, 2025, 8:12 AM EDT - 8 months ago

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:00 AM EDT - 8 months ago

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Evaxion Transcript: Investor Update

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Evaxion Transcript: Investor Update

Evaxion Press release: Investor Update

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Evaxion Press release: Investor Update

Evaxion Slides: Investor Update

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Evaxion Slides: Investor Update

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Sep 25, 2025, 7:00 AM EDT - 9 months ago

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Evaxion Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 10 months ago

Evaxion Earnings Call Transcript: Q2 2025

Evaxion Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 10 months ago

Evaxion Earnings release: Q2 2025

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Jul 25, 2025, 9:00 AM EDT - 11 months ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion finalizes agreement with EIB to convert debt into equity

Jul 11, 2025, 8:00 AM EDT - 11 months ago

Evaxion finalizes agreement with EIB to convert debt into equity

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jul 1, 2025, 8:30 AM EDT - 1 year ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 25, 2025, 8:00 AM EDT - 1 year ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Evaxion receives grant funding to design new polio vaccine

Jun 3, 2025, 9:15 AM EDT - 1 year ago

Evaxion receives grant funding to design new polio vaccine

Evaxion Earnings Call Transcript: Q1 2025

May 27, 2025, 8:30 AM EDT - 1 year ago

Evaxion Earnings Call Transcript: Q1 2025

Evaxion Earnings release: Q1 2025

May 27, 2025, 8:30 AM EDT - 1 year ago

Evaxion Earnings release: Q1 2025

Evaxion announces business update and first quarter 2025 financial results

May 27, 2025, 7:30 AM EDT - 1 year ago

Evaxion announces business update and first quarter 2025 financial results

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 23, 2025, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

Evaxion Transcript: Sidoti May Micro-Cap Virtual Conference

May 22, 2025, 12:15 PM EDT - 1 year ago

Evaxion Transcript: Sidoti May Micro-Cap Virtual Conference

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

May 22, 2025, 8:00 AM EDT - 1 year ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 28, 2025, 8:00 AM EDT - 1 year ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Evaxion to present at World Vaccine Congress

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Evaxion to present at World Vaccine Congress

Evaxion Transcript: Jones Healthcare and Technology Innovation Conference 2025

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Evaxion Transcript: Jones Healthcare and Technology Innovation Conference 2025

Evaxion Earnings Call Transcript: Q4 2024

Apr 1, 2025, 8:30 AM EDT - 1 year ago

Evaxion Earnings Call Transcript: Q4 2024

Evaxion Annual report: Q4 2024

Apr 1, 2025, 8:30 AM EDT - 1 year ago

Evaxion Annual report: Q4 2024

Evaxion Earnings release: Q4 2024

Apr 1, 2025, 8:30 AM EDT - 1 year ago

Evaxion Earnings release: Q4 2024

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion Registration statement: Registration Filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Evaxion Registration statement: Registration Filing

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Feb 25, 2025, 8:00 AM EST - 1 year ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Evaxion Transcript: Fireside Chat

Feb 19, 2025, 10:00 AM EST - 1 year ago

Evaxion Transcript: Fireside Chat

Evaxion announces closing of $10.8 million public offering

Jan 31, 2025, 4:05 PM EST - 1 year ago

Evaxion announces closing of $10.8 million public offering

Evaxion announces pricing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 1 year ago

Evaxion announces pricing of $10.8 million public offering

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 28, 2025, 8:15 AM EST - 1 year ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Evaxion Registration statement: Registration Filing

Jan 28, 2025, 7:00 AM EST - 1 year ago

Evaxion Registration statement: Registration Filing

Evaxion announces completion of ADS ratio change

Jan 14, 2025, 4:05 PM EST - 1 year ago

Evaxion announces completion of ADS ratio change

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Jan 10, 2025, 8:00 AM EST - 1 year ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Evaxion announces plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 1 year ago

Evaxion announces plan to implement ADS ratio change

Evaxion Registration statement: Registration Filing

Dec 17, 2024, 7:00 AM EST - 1 year ago

Evaxion Registration statement: Registration Filing

Evaxion Registration statement: Registration Filing

Dec 5, 2024, 7:00 AM EST - 1 year ago

Evaxion Registration statement: Registration Filing

Evaxion Registration statement: Registration Filing

Nov 18, 2024, 7:00 AM EST - 1 year ago

Evaxion Registration statement: Registration Filing

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Nov 12, 2024, 8:00 AM EST - 1 year ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Evaxion Earnings Call Transcript: Q3 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Evaxion Earnings Call Transcript: Q3 2024

Evaxion Earnings release: Q3 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Evaxion Earnings release: Q3 2024

Evaxion announces business update and third quarter 2024 financial results

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evaxion announces business update and third quarter 2024 financial results

ChaChing777
ChaChing777 Jun. 4 at 5:14 PM
$EVAX Feels like something is brewing. We’re getting some movement in the right direction. 
1 · Reply
TheDragonsClaw
TheDragonsClaw Jun. 4 at 9:27 AM
$SEGG $CPIX $IBO $EVAX Need more news!
0 · Reply
topstockalerts
topstockalerts Jun. 3 at 10:20 PM
$EVAX the chart is starting to attract more attention.
0 · Reply
ChaChing777
ChaChing777 Jun. 3 at 9:31 PM
$EVAX Hopefully soon. This things take a little time.
1 · Reply
Whtmtn
Whtmtn Jun. 3 at 12:31 PM
$EVAX any strategic deals happening here per Helen’s repeated claims of progress?
0 · Reply
Manwiththeplan
Manwiththeplan Jun. 3 at 10:55 AM
$EVAX i am a big fan of the science here. But i am now waiting 2 years for significant new business developement. I gave it to may 2026 and now i will be reducing my position a bit. Made profit during last run up, but i am losing faith a bit
3 · Reply
Manwiththeplan
Manwiththeplan Jun. 2 at 6:20 PM
$EVAX
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 2 at 12:06 AM
$EVAX
0 · Reply
NoNoNoNoNoNoYesNo
NoNoNoNoNoNoYesNo May. 27 at 7:41 PM
$EVAX I bought more today below 4. Still holding for that next pump. Just a matter of time
0 · Reply
Manwiththeplan
Manwiththeplan May. 23 at 7:20 PM
$BCTX $EVAX are my best voor 2026. Low market caps. High potential
1 · Reply
Manwiththeplan
Manwiththeplan May. 22 at 8:12 PM
$EVAX deal in 14 days!
1 · Reply
ChaChing777
ChaChing777 May. 22 at 4:00 PM
$EVAX Any day now! 🧨
0 · Reply
Rebirth_Coldblooded
Rebirth_Coldblooded May. 19 at 10:56 PM
$OSRH volume dead. The only savior is a milestone payment. I remember a licensing deal for $EVAX with Merck for 500m. Months ago, still no milestone payments but the stock ran pretty hard for days. Something very fishy about that day when the news was announced for OSRH and it couldn’t even take a local high. Is this a honeypot?
2 · Reply
Manwiththeplan
Manwiththeplan May. 19 at 7:44 PM
$EVAX
0 · Reply
MortenFromDenmark
MortenFromDenmark May. 19 at 9:06 AM
$EVAX
1 · Reply
Manwiththeplan
Manwiththeplan May. 18 at 12:13 PM
$EVAX Evaxion Biotech Australia Pty Ltd 640 359 637 | Members' Voluntary Liquidation | Appointment | Select One | Published : 15/05/2026 | ASIC Notice Details https://share.google/pMynxD5j6uVCcd8Pt Think are happening.... 🤔
1 · Reply
Whtmtn
Whtmtn May. 15 at 6:40 PM
$EVAX hey Helen how are those strategic discussions going? Must be imminent.
1 · Reply
Manwiththeplan
Manwiththeplan May. 14 at 8:26 PM
$EVAX waiting 1,5 years for a new deal
0 · Reply
Manwiththeplan
Manwiththeplan May. 12 at 5:57 PM
$EVAX
1 · Reply
Manwiththeplan
Manwiththeplan May. 12 at 4:56 PM
$EVAX
0 · Reply
Lenni_D
Lenni_D May. 12 at 2:40 PM
$EVAX Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress. https://evaxion.ai/investors/press-releases/?press_release_id=11176 More great data coming. I have no doubt it’ll be amazing. But no one gives a F. That’s the problem when you over promise and under deliver on partnerships year after year. NOW they are going to focus on partnerships. Well that’s what they said when they hired the former CEO a few years back and they still missed the ‘milestones’ every year. The difference now is they have stopped guiding revenue from deals. Always frustrating when companies have great science and bad management. I think it’s a big problem that MSD is a major shareholder. And the useless former CEO even bragged about how MSD stopped a deal with another partner to license EVX-B2 when the terms had been negotiated. Only to see MSD not exercise the option later. That drug could have been well underway.
0 · Reply
Manwiththeplan
Manwiththeplan May. 11 at 7:35 PM
$EVAX
0 · Reply